To further assess the in vivo anti-proliferative and anti-angiogenic effects of F2, tumor samples were analyzed by immunohistochemistry for Ki67 (a cell proliferation biomarker) and CD31 (a marker of endothelial cells). The gene discussed is PECAM1; the disease is neoplasm.